Drug intelligence / Profile preview

Dexozyme

Development stage: Unknown
Lead developer: Dexon Biotech
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

Dexozyme is a combination digestive enzyme formulation containing fungal diastase and pepsin. Developed by Dexon Biotech, it is primarily used to treat digestive disorders, including indigestion, flatulence, bloating, and loss of appetite. Fungal diastase is a starch-degrading enzyme derived from fungal sources (such as *Aspergillus oryzae*) that facilitates the breakdown of complex carbohydrates into simpler sugars. Pepsin is a proteolytic enzyme that aids in the digestion of dietary proteins by cleaving them into smaller peptides in the acidic environment of the stomach. Together, these enzymes supplement the body's natural digestive secretions, promoting efficient nutrient absorption and relieving gastrointestinal discomfort.

Brand names: Dexozyme
Other names: Dexozyme Oral DropsDexozyme Syrup

Beyond the preview

Go deeper on Dexozyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dexozyme.

Explore the full profile